MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
September 27, 2006
Ralph Casale
Qiagen: Biotech Support Is this biotech industry leader an attractive investment? While this is a quality company operating an attractive business, investors may want to wait for a better price before adding it to a portfolio. mark for My Articles similar articles
The Motley Fool
August 16, 2007
Brian Orelli
More Drugmaker Growth Without the FDA All that high-tech lab equipment has to come from somewhere. Here's how investors can benefit from it, too. mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2011
Jill Wechsler
The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome? mark for My Articles similar articles
Bio-IT World
March 2007
Robert M. Frederickson
The Market for Automation The QIAcube is a benchtop robotic system for fully automated sample preparation using the Qiagen spin-column kits that are currently in wide use. mark for My Articles similar articles
Bio-IT World
March 2006
Michael A. Greeley
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain. mark for My Articles similar articles
Bio-IT World
January 12, 2004
Kevin Davies
The Ultimate Platform Firm Greg Lucier on determinism in drug development at Invitrogen mark for My Articles similar articles
Chemistry World
March 16, 2011
Inspirational science Seong Keun Kim is head of the Molecular Reaction Dynamics Laboratory at Seoul National University, Korea. He uses spectroscopic, microscopic and computational methods to investigate a wide range of subjects from molecular physics and nanoscience to cell biology. mark for My Articles similar articles
Bio-IT World
August 13, 2002
Mark D. Uehling
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? mark for My Articles similar articles
The Motley Fool
December 30, 2003
Tom Taulli
M&A As Strong Medicine Invitrogen's latest deal shows that the company knows where its market is headed. mark for My Articles similar articles
The Motley Fool
February 7, 2008
Brian Orelli
Invitrogen Integrates After a rough 2006 in which it struggled to integrate its acquisitions, Invitrogen used 2007 to show why it made all of its purchases. mark for My Articles similar articles
The Motley Fool
August 17, 2007
Brian Orelli
Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully. mark for My Articles similar articles
HHMI Bulletin
Nov 2011
Sarah C.P. Williams.
Carolyn Bertozzi: Changed Expectations Chemists trained in biology were once a rarity -- now they're becoming the norm. mark for My Articles similar articles
Bio-IT World
January 21, 2005
How IT Can Decrease Time-to-Market in Clinical Trials Pharma manufacturers can learn from their industrial counterparts: Integrating systems can accelerate product delivery. mark for My Articles similar articles
The Motley Fool
January 31, 2006
Stephen D. Simpson
Poring Over Millipore The life sciences R&D industry has room to grow. This stock price may not. mark for My Articles similar articles
The Motley Fool
February 16, 2010
Brian Orelli
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. mark for My Articles similar articles
Chemistry World
June 17, 2015
Moray Stark
Safe science: promoting a culture of safety in academic chemical research The drive for this timely book has been a number of serious, and sometimes fatal, accidents in US university chemistry labs. mark for My Articles similar articles
The Motley Fool
February 15, 2006
Stephen D. Simpson
A Play on the Building Blocks of R&D Sigma-Aldrich might be suitable for those looking to play biological R&D without picking a specific pharma or biotech stock. mark for My Articles similar articles
Bio-IT World
September 2005
Bill Van Etten
'If We Can Put a Man on the Moon . . .' Before the U.S. stops producing scientists, before we outlaw scientific research and knowledge altogether, scientists must make their best effort to bring science to the mainstream by familiarizing their children and their communities with who they are and what they do. mark for My Articles similar articles
The Motley Fool
June 29, 2005
Karl Thiel
Cash In on the Future of Science With some diligence, you can ride your high school biology to biotech investing success. mark for My Articles similar articles
Bio-IT World
September 16, 2004
Paul King
Growing Gains When it comes to information technology requirements, the biotech industry is unlike any other. A key enabler of efficient and effective growth is the adoption of IT strategies specific to each of four key stages. mark for My Articles similar articles
Chemistry World
September 12, 2008
Rebecca Trager
NIH funds chemical biology network NIH-funded scientists will have access to the tools for rapidly screening hundreds of thousands of small molecules against many novel biological assays at lower costs than previously possible,' said the agency's director, Elias Zerhouni. mark for My Articles similar articles
HHMI Bulletin
Fall 2012
Robert Tjian
President's Letter: Stabilizing Forces Recognizing the role of research professionals in today's laboratory organizations is important not only to the individuals who contribute their services but also to the research enterprise as a whole. mark for My Articles similar articles
Chemistry World
January 2012
Cultivating collaboration A new network aims to bring the power of interdisciplinary innovation to bear on global food issues. mark for My Articles similar articles
Chemistry World
July 6, 2012
Protein power Tom Muir, professor of chemistry and molecular biology, Princeton University, US, is an expert in protein engineering and its application to studying cellular signalling networks. mark for My Articles similar articles
Chemistry World
May 1, 2014
Ned Stafford
Synthetic biology vision for Europe unveiled A new 'strategic vision' for synthetic biology has laid out the steps Europe needs to take in the next five to 10 year to nurture the field, with chemistry a key part of its strategy. mark for My Articles similar articles
Bio-IT World
November 14, 2003
Hoffer et al.
Over the Rainbow Yet? Consolidation slows, valuations grow, and now there's hope for some biotech IPOs. mark for My Articles similar articles
Bio-IT World
August 2005
Maureen McDonough
Invitrogen Launches iPath Invitrogen has unveiled a free bioinformatics and systems biology research tool that can be found on the company's Web site. iPath allows users to click their way through 2,500 human genes, 171 signal transduction pathways, and 54 metabolic pathways. mark for My Articles similar articles
The Motley Fool
January 30, 2007
Ralph Casale
Molecular Devices Acquired Successful integration of companies like Molecular Devices and improvement of operating margins in the pharmaceutical contract research business unit should reward shareholders well. mark for My Articles similar articles
Bio-IT World
February 10, 2003
Salvatore Salamone
Made in Manhattan A talk with the new head of the Computational Biology Center at Memorial Sloan-Kettering. mark for My Articles similar articles
Chemistry World
April 11, 2012
Mico Tatalovic
Croatian scientists call for chemical reagent regulation Prominent Croatian scientists are calling for better regulation of the domestic market for laboratory chemicals and reagents as prices can be as much as 70% higher than in other European countries. mark for My Articles similar articles
National Defense
June 2010
Stew Magnuson
Growing Public Interest In Genetic Science Sparks Some Bio-Security Concerns A growing movement of hobbyists who are carrying out biology experiments in garages, basements and community labs has drawn some interest from the FBI. mark for My Articles similar articles
Bio-IT World
March 2006
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. mark for My Articles similar articles
Chemistry World
September 13, 2012
Andy Merritt
Chemical biology comes of age Historically strongest in the US, chemical biology has become increasingly important worldwide, but for many years researchers at the chemistry -- biology interface have struggled to establish their discipline mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? mark for My Articles similar articles
Bio-IT World
December 15, 2003
Zachary Zimmerman
Learning the Language of Systems Biology Geneticist par excellence David Botstein talks about his philosophy, science, his mission for integrative science, and what he deems a success for systems biology. mark for My Articles similar articles
Chemistry World
June 25, 2015
Rebecca Trager
NIH plan to get drug development unit back online The NIH has set out key milestones in its plan, including training and re-training personnel in good manufacturing practice regulations by August. mark for My Articles similar articles
Bio-IT World
September 9, 2002
Letters Frustrated in Gene Town... IT for the Biologists, by the Biologists?... mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2012
Jill Wechsler
Shortages and Sunshine Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors. mark for My Articles similar articles
Reason
June 2005
Kerry Howley
Scientists for Sale Innovation vs. ethics: Scientists at the NIH have discovered many things over the years, but evidently they haven't yet found a way to balance innovation and objectivity. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2012
Ron Cohen
FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership. mark for My Articles similar articles
The Motley Fool
July 26, 2006
Ryan Fuhrmann
Sigma-Aldrich's Steady Growth Growth at this life science company is steady, not spectacular. With a current stock price of $67.78, the shares trade at about 17 times projected earnings. mark for My Articles similar articles
The Motley Fool
May 5, 2004
Brian Gorman
Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas. mark for My Articles similar articles
Chemistry World
March 19, 2007
Jessica Ebert
Pocket-Sized PCR Machine Scientists in the US report being one step closer to designing a miniaturized, portable polymerase chain reaction machine that could be used for applications such as point-of-care diagnostics. mark for My Articles similar articles
The Motley Fool
January 4, 2007
Ralph Casale
Picks and Shovels of Biotechnology Biotech investors will continue to venture into the dark mines of burgeoning pharmaceutical firms. There is certainly gold to be found in some of them, just remember to invest in some of the hardware stores of biotechnology along the way. mark for My Articles similar articles
Bio-IT World
August 2005
Ellen H. Julian
Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources. mark for My Articles similar articles
Chemistry World
June 8, 2015
Rebecca Trager
NIH drug manufacturing unit shut down The halt could potentially affect 46 clinical trials, and about 250 patients who are either receiving, or about to receive, products manufactured at the facility. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2012
Jill Wechsler
Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market. mark for My Articles similar articles
HBS Working Knowledge
January 5, 2011
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress Society pays a high price for randomization of research support -- a fact that, sadly, is not recognized by the public, the media, or politicians. mark for My Articles similar articles
BusinessWeek
November 6, 2006
Nichola Saminather
Biotech's Beef There is a disconnect between what universities are teaching and what biotech wants. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2013
Jill Wechsler
Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies. mark for My Articles similar articles